View Financial HealthBioHarvest Sciences 배당 및 자사주 매입배당 기준 점검 0/6BioHarvest Sciences 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-52.7%자사주 매입 수익률총 주주 수익률-52.7%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 28BioHarvest Sciences Inc. to Report Q2, 2026 Results on Aug 11, 2026BioHarvest Sciences Inc. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on Aug 11, 2026공고 • Jul 15BioHarvest Sciences Inc. Receives $1.4 Million Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell SynthesisBioHarvest Sciences Inc. has received approval for a NIS 4.33 million (approximately USD 1.4 million) grant from the Israel Innovation Authority. This non-dilutive funding will support a new research initiative at BioHarvest integrating advanced data science, machine learning, computer vision and high-throughput digital sensing directly into BioHarvest’s biological development workflows, thereby accelerating its plant cell culture programs. BioHarvest's new approved research initiative focuses on moving plant cell culture from traditional empirical trial-and-error methods to a highly predictable, data-driven optimization framework. Specifically, by combining bioinformatics, chemo-informatics and artificial intelligence, the platform will systematically predict the success of plant cell propagation and dramatically maximize active metabolite yields. The program will accelerate the development of BioHarvest's advanced computational discovery engine. This platform integrates proprietary predictive machine learning models with real-time digital sensing to rapidly identify optimal pathways and maximize bioactive yields across diverse plant species. Supported by secure, domain-specific scientific knowledge bases, these new capabilities will streamline early-stage R&D, transforming how complex plant-based compounds are forecasted, monitored, and scaled. This marks the second grant BioHarvest has received from the Israel Innovation Authority this year. While the first grant was dedicated to scaling the manufacturing facility by integrating industrial automation and machine learning on the factory floor, this second grant is focused on transforming the early-stage R&D pipeline through predictive AI. Together, these two distinct yet highly complementary initiatives fuel a technological transformation across the company-bridging the gap between intelligent, data-driven laboratory discovery and high-volume, autonomous commercial production. The grant was provided by the Israel Innovation Authority in the form of a non-dilutive, zero-interest loan. Repayment is contingent upon the achievement of certain predefined commercial milestones and is expected to be made solely from future revenues generated by the funded project. No equity or equity-linked instruments were issued in connection with the grant.Reported Earnings • May 16First quarter 2026 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2025)First quarter 2026 results: US$0.12 loss per share. Revenue: US$8.51m (up 8.2% from 1Q 2025). Net loss: US$2.64m (loss widened 13% from 1Q 2025). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe.공고 • May 02BioHarvest Sciences Inc. to Report Q1, 2026 Results on May 14, 2026BioHarvest Sciences Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026Breakeven Date Change • Apr 06Forecast breakeven date pushed back to 2028The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 40% per year to 2027. The company is expected to make a profit of US$15.1m in 2028. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Reported Earnings • Apr 02Full year 2025 earnings released: US$0.60 loss per share (vs US$0.80 loss in FY 2024)Full year 2025 results: US$0.60 loss per share (improved from US$0.80 loss in FY 2024). Revenue: US$34.5m (up 37% from FY 2024). Net loss: US$11.1m (loss narrowed 14% from FY 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Personal Products industry in Europe.공고 • Mar 17BioHarvest Sciences Inc. to Report Q4, 2025 Results on Mar 31, 2026BioHarvest Sciences Inc. announced that they will report Q4, 2025 results After-Market on Mar 31, 2026공고 • Dec 05BioHarvest Sciences Inc. Announces Launch of VINIA Blood Flow Hydration ProductBioHarvest Sciences Inc. announced the U.S. launch of VINIA Blood Flow Hydration, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolyte Market. Better Hydration starts with Better Blood Flow. Following overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydation™? is now shipping nationwide and is available exclusively at Vinia.com, with free delivery across North America. This product introduces a breakthrough concept to the rapidly growing hydration market: Hydration Powered by the Blood Flow benefits of VINIA'sPiceid Resveratrol, marking VINIA Blood Flow Hydrated™? as the world's first hydration formula with the power of VINIA's rapid absorption Piceid Resveratrol - designed to work synergistically to improve the body's circulation system and more efficiently deliver fluids and electrolytes where the body needs it most. VINIA Blood flow goes one step further and improves How electrolytes and nutrients get delivered. Containing the finest sources of natural electrolytes, the solution is formulated with premium sodium from sea salt, potassium from coconut water, and magnesium from marine ocean beds. This electrolyte solution is powered by VINIA's unique red grape polyphenol complex (23mg), including rapid absorption Piceid Res Veratrol (6mg), which has been clinically shown to significantly increase arterial dilation, improving blood flow. Better blood flow ensures more efficient transportation of electrolytes and fluids to body's organs, muscles, and cells, right where they're needed most. A New Era in Blood Flow-Driven Hydration Science. Products undergo rigorous testing using ISO 17025 accredited methods to provide the highest level of assurance for athletes. Every order is backed by BioHarvest's 90-Day "Feel It or It's Free" Guarantee, the industry's strongest consumer promise. Customers can use every stick for 90 days. If they do not love the taste or feel the VINIA®? difference, VINIA®? will refund the full purchase price and cover return shipping. No questions asked. The company has announced that VINIA Blood Flow Hydization is now available to all online consumers for purchase on VINIA.com and will be available on Amazon.com by the end of December. In addition to being available direct-to-consumer via the company's established e-commerce channels, VINIA Blood Flow hydration will also be distributed via select "point-of-sweat" outlets, to service active consumers looking for premium health solutions.Breakeven Date Change • Nov 15Forecast breakeven date moved forward to 2026The 3 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 15% to 2025. The company is expected to make a profit of US$1.08m in 2026. Average annual earnings growth of 74% is required to achieve expected profit on schedule.New Risk • Nov 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$4.2m). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding).공고 • Nov 07+ 1 more updateBioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million.BioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,485,000 Price\Range: $7공고 • Nov 05BioHarvest Sciences Inc. to Report Q3, 2025 Results on Nov 13, 2025BioHarvest Sciences Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025공고 • Oct 06BioHarvest Sciences Inc. announced that it has received CAD 0.553037 million in fundingOn October 6, 2025, BioHarvest Sciences Inc. closed the transaction.공고 • Sep 24BioHarvest Sciences Inc. announced that it has received CAD 5.1 million in fundingBioHarvest Sciences Inc announced that it has completed a private placement and issued Convertible Notes for aggregate gross proceeds of CAD 5,100,000 on September 22, 2025.Breakeven Date Change • Sep 22Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 29Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Reported Earnings • Aug 14Second quarter 2025 earnings released: US$0.23 loss per share (vs US$0.042 loss in 2Q 2024)Second quarter 2025 results: US$0.23 loss per share (further deteriorated from US$0.042 loss in 2Q 2024). Revenue: US$8.52m (up 41% from 2Q 2024). Net loss: US$4.08m (loss widened 494% from 2Q 2024). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Personal Products industry in Europe.Breakeven Date Change • Aug 13The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 25% to 2025. The company is expected to make a profit of US$49.8k in 2026. Average annual earnings growth of 73% is required to achieve expected profit on schedule.공고 • Aug 04BioHarvest Sciences Inc. to Report Q2, 2025 Results on Aug 11, 2025BioHarvest Sciences Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 11, 2025공고 • Jun 05BioHarvest Sciences Inc. Announces the Launch of VINIA® DailyChews 2X FormulaBioHarvest Sciences Inc. announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com. Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike.Reported Earnings • May 16First quarter 2025 earnings released: US$0.14 loss per share (vs US$0.48 loss in 1Q 2024)First quarter 2025 results: US$0.14 loss per share (improved from US$0.48 loss in 1Q 2024). Revenue: US$7.86m (up 47% from 1Q 2024). Net loss: US$2.34m (loss narrowed 65% from 1Q 2024). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Personal Products industry in Europe.공고 • May 02BioHarvest Sciences Inc. to Report Q1, 2025 Results on May 15, 2025BioHarvest Sciences Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025공고 • Mar 17BioHarvest Sciences Inc. to Report Q4, 2024 Results on Mar 31, 2025BioHarvest Sciences Inc. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 8MV0 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 8MV0 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장BioHarvest Sciences 배당 수익률 vs 시장8MV0의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (8MV0)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.7%업계 평균 (Personal Products)2.4%분석가 예측 (8MV0) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 8MV0 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 8MV0 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 8MV0 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 8MV0 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/11 00:39종가2026/07/28 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BioHarvest Sciences Inc.는 4명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Matthew HewittCraig-Hallum Capital Group LLCAmit DayalH.C. Wainwright & Co.Anthony VendettiMaxim Group1명의 분석가 더 보기
공고 • Jul 28BioHarvest Sciences Inc. to Report Q2, 2026 Results on Aug 11, 2026BioHarvest Sciences Inc. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on Aug 11, 2026
공고 • Jul 15BioHarvest Sciences Inc. Receives $1.4 Million Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell SynthesisBioHarvest Sciences Inc. has received approval for a NIS 4.33 million (approximately USD 1.4 million) grant from the Israel Innovation Authority. This non-dilutive funding will support a new research initiative at BioHarvest integrating advanced data science, machine learning, computer vision and high-throughput digital sensing directly into BioHarvest’s biological development workflows, thereby accelerating its plant cell culture programs. BioHarvest's new approved research initiative focuses on moving plant cell culture from traditional empirical trial-and-error methods to a highly predictable, data-driven optimization framework. Specifically, by combining bioinformatics, chemo-informatics and artificial intelligence, the platform will systematically predict the success of plant cell propagation and dramatically maximize active metabolite yields. The program will accelerate the development of BioHarvest's advanced computational discovery engine. This platform integrates proprietary predictive machine learning models with real-time digital sensing to rapidly identify optimal pathways and maximize bioactive yields across diverse plant species. Supported by secure, domain-specific scientific knowledge bases, these new capabilities will streamline early-stage R&D, transforming how complex plant-based compounds are forecasted, monitored, and scaled. This marks the second grant BioHarvest has received from the Israel Innovation Authority this year. While the first grant was dedicated to scaling the manufacturing facility by integrating industrial automation and machine learning on the factory floor, this second grant is focused on transforming the early-stage R&D pipeline through predictive AI. Together, these two distinct yet highly complementary initiatives fuel a technological transformation across the company-bridging the gap between intelligent, data-driven laboratory discovery and high-volume, autonomous commercial production. The grant was provided by the Israel Innovation Authority in the form of a non-dilutive, zero-interest loan. Repayment is contingent upon the achievement of certain predefined commercial milestones and is expected to be made solely from future revenues generated by the funded project. No equity or equity-linked instruments were issued in connection with the grant.
Reported Earnings • May 16First quarter 2026 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2025)First quarter 2026 results: US$0.12 loss per share. Revenue: US$8.51m (up 8.2% from 1Q 2025). Net loss: US$2.64m (loss widened 13% from 1Q 2025). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe.
공고 • May 02BioHarvest Sciences Inc. to Report Q1, 2026 Results on May 14, 2026BioHarvest Sciences Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026
Breakeven Date Change • Apr 06Forecast breakeven date pushed back to 2028The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 40% per year to 2027. The company is expected to make a profit of US$15.1m in 2028. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Reported Earnings • Apr 02Full year 2025 earnings released: US$0.60 loss per share (vs US$0.80 loss in FY 2024)Full year 2025 results: US$0.60 loss per share (improved from US$0.80 loss in FY 2024). Revenue: US$34.5m (up 37% from FY 2024). Net loss: US$11.1m (loss narrowed 14% from FY 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Personal Products industry in Europe.
공고 • Mar 17BioHarvest Sciences Inc. to Report Q4, 2025 Results on Mar 31, 2026BioHarvest Sciences Inc. announced that they will report Q4, 2025 results After-Market on Mar 31, 2026
공고 • Dec 05BioHarvest Sciences Inc. Announces Launch of VINIA Blood Flow Hydration ProductBioHarvest Sciences Inc. announced the U.S. launch of VINIA Blood Flow Hydration, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolyte Market. Better Hydration starts with Better Blood Flow. Following overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydation™? is now shipping nationwide and is available exclusively at Vinia.com, with free delivery across North America. This product introduces a breakthrough concept to the rapidly growing hydration market: Hydration Powered by the Blood Flow benefits of VINIA'sPiceid Resveratrol, marking VINIA Blood Flow Hydrated™? as the world's first hydration formula with the power of VINIA's rapid absorption Piceid Resveratrol - designed to work synergistically to improve the body's circulation system and more efficiently deliver fluids and electrolytes where the body needs it most. VINIA Blood flow goes one step further and improves How electrolytes and nutrients get delivered. Containing the finest sources of natural electrolytes, the solution is formulated with premium sodium from sea salt, potassium from coconut water, and magnesium from marine ocean beds. This electrolyte solution is powered by VINIA's unique red grape polyphenol complex (23mg), including rapid absorption Piceid Res Veratrol (6mg), which has been clinically shown to significantly increase arterial dilation, improving blood flow. Better blood flow ensures more efficient transportation of electrolytes and fluids to body's organs, muscles, and cells, right where they're needed most. A New Era in Blood Flow-Driven Hydration Science. Products undergo rigorous testing using ISO 17025 accredited methods to provide the highest level of assurance for athletes. Every order is backed by BioHarvest's 90-Day "Feel It or It's Free" Guarantee, the industry's strongest consumer promise. Customers can use every stick for 90 days. If they do not love the taste or feel the VINIA®? difference, VINIA®? will refund the full purchase price and cover return shipping. No questions asked. The company has announced that VINIA Blood Flow Hydization is now available to all online consumers for purchase on VINIA.com and will be available on Amazon.com by the end of December. In addition to being available direct-to-consumer via the company's established e-commerce channels, VINIA Blood Flow hydration will also be distributed via select "point-of-sweat" outlets, to service active consumers looking for premium health solutions.
Breakeven Date Change • Nov 15Forecast breakeven date moved forward to 2026The 3 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 15% to 2025. The company is expected to make a profit of US$1.08m in 2026. Average annual earnings growth of 74% is required to achieve expected profit on schedule.
New Risk • Nov 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$4.2m). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding).
공고 • Nov 07+ 1 more updateBioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million.BioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,485,000 Price\Range: $7
공고 • Nov 05BioHarvest Sciences Inc. to Report Q3, 2025 Results on Nov 13, 2025BioHarvest Sciences Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
공고 • Oct 06BioHarvest Sciences Inc. announced that it has received CAD 0.553037 million in fundingOn October 6, 2025, BioHarvest Sciences Inc. closed the transaction.
공고 • Sep 24BioHarvest Sciences Inc. announced that it has received CAD 5.1 million in fundingBioHarvest Sciences Inc announced that it has completed a private placement and issued Convertible Notes for aggregate gross proceeds of CAD 5,100,000 on September 22, 2025.
Breakeven Date Change • Sep 22Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 29Forecast breakeven date pushed back to 2027The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Reported Earnings • Aug 14Second quarter 2025 earnings released: US$0.23 loss per share (vs US$0.042 loss in 2Q 2024)Second quarter 2025 results: US$0.23 loss per share (further deteriorated from US$0.042 loss in 2Q 2024). Revenue: US$8.52m (up 41% from 2Q 2024). Net loss: US$4.08m (loss widened 494% from 2Q 2024). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Personal Products industry in Europe.
Breakeven Date Change • Aug 13The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 25% to 2025. The company is expected to make a profit of US$49.8k in 2026. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
공고 • Aug 04BioHarvest Sciences Inc. to Report Q2, 2025 Results on Aug 11, 2025BioHarvest Sciences Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 11, 2025
공고 • Jun 05BioHarvest Sciences Inc. Announces the Launch of VINIA® DailyChews 2X FormulaBioHarvest Sciences Inc. announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com. Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike.
Reported Earnings • May 16First quarter 2025 earnings released: US$0.14 loss per share (vs US$0.48 loss in 1Q 2024)First quarter 2025 results: US$0.14 loss per share (improved from US$0.48 loss in 1Q 2024). Revenue: US$7.86m (up 47% from 1Q 2024). Net loss: US$2.34m (loss narrowed 65% from 1Q 2024). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Personal Products industry in Europe.
공고 • May 02BioHarvest Sciences Inc. to Report Q1, 2025 Results on May 15, 2025BioHarvest Sciences Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025
공고 • Mar 17BioHarvest Sciences Inc. to Report Q4, 2024 Results on Mar 31, 2025BioHarvest Sciences Inc. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025